Anti-GD2 antibody
Pre-clinical- Indications
- Neuroblastoma
Company intelligence / Profile preview
Alga Biologics
Isneauville, Normandie, Francealgabiologics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Preliminary results of preclinical study for neuroblastoma antibody are promising and demonstrate functionality of the antibody produced in microalgae[3]
- Therapeutic areas
- Oncology
- Modalities
- Recombinant proteinsantibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Collaborates with academic institutions, bioproduction players, and pharmaceutical companies[3]
Beyond the preview
Go deeper on Alga Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alga Biologics.